Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AFMD Affimed	$0.18 -34.9%	$0.25	$0.07 ▼ $5.52	$2.92M	2.07	4.81 million shs	22.99 million shs
GALT Galectin Therapeutics	$2.80 -3.1%	$1.85	$0.73 ▼ $3.90	$177.21M	0.7	420,032 shs	443,809 shs
NEPT Neptune Wellness Solutions		$0.39	$0.19 ▼ $28.00	$906K	2.19	462,687 shs	2.25 million shs
OASM Oasmia Pharmaceutical AB (publ)	$0.02	$1.46	$0.94 ▼ $5.70	$1.50M	0.96	98,414 shs	N/A
THTX Theratechnologies	$3.14 -0.3%	$2.67	$1.12 ▼ $3.20	$144.38M	0.55	898,727 shs	355,140 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AFMD Affimed	0.00%	0.00%	0.00%	-75.26%	-96.72%
GALT Galectin Therapeutics	+1.40%	+17.96%	+20.92%	+109.42%	+12.23%
NEPT Neptune Wellness Solutions	0.00%	0.00%	0.00%	0.00%	0.00%
OASM Oasmia Pharmaceutical AB (publ)	0.00%	0.00%	0.00%	0.00%	-59.92%
THTX Theratechnologies	0.00%	-0.32%	+27.64%	+24.60%	+104.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AFMD Affimed	3.0319 of 5 stars	4.0	0.0	0.0	4.3	1.1	0.0	1.3
GALT Galectin Therapeutics	2.1154 of 5 stars	3.5	2.0	0.0	0.0	2.7	1.7	0.0
NEPT Neptune Wellness Solutions	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AFMD Affimed	2.00	Hold	$3.62	1,895.87% Upside
GALT Galectin Therapeutics	3.00	Buy	$6.00	114.29% Upside
NEPT Neptune Wellness Solutions	0.00	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	0.00	N/A	N/A	N/A
THTX Theratechnologies	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest GALT, AFMD, NEPT, THTX, and OASM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	THTX Theratechnologies	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/17/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/14/2025	AFMD Affimed	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/14/2025	AFMD Affimed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/13/2025	AFMD Affimed	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/13/2025	AFMD Affimed	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$11.00 ➝ $0.10
5/13/2025	AFMD Affimed	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$5.00 ➝ $0.39

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AFMD Affimed	$877K	3.33	N/A	N/A	$4.19 per share	0.04
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.68) per share	N/A
NEPT Neptune Wellness Solutions	$52.62M	0.00	N/A	N/A	($91.90) per share	0.00
OASM Oasmia Pharmaceutical AB (publ)	$220K	6.82	N/A	N/A	$0.63 per share	0.03
THTX Theratechnologies	$85.87M	1.68	N/A	N/A	($0.61) per share	-5.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AFMD Affimed	-$114.66M	N/A	0.00	N/A	N/A	-7,836.26%	-193.84%	-107.24%	9/1/2025 (Estimated)
GALT Galectin Therapeutics	-$47.05M	-$0.72	N/A	N/A	N/A	N/A	N/A	-216.05%	8/12/2025 (Estimated)
NEPT Neptune Wellness Solutions	-$60.46M	-$106.72	N/A	N/A	N/A	-128.13%	N/A	-141.94%	N/A
OASM Oasmia Pharmaceutical AB (publ)	-$18.95M	N/A	0.00	∞	N/A	-8,633.64%	-43.94%	-28.92%	N/A
THTX Theratechnologies	-$8.31M	-$0.19	N/A	44.86	N/A	-10.85%	N/A	-9.83%	N/A

Latest GALT, AFMD, NEPT, THTX, and OASM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	GALT Galectin Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
7/9/2025	Q2 2025	THTX Theratechnologies	-$0.01	-$0.09	-$0.08	-$0.09	$24.30 million	$17,729.00 billion
5/15/2025	Q1 2025	GALT Galectin Therapeutics	-$0.20	-$0.15	+$0.05	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AFMD Affimed	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
NEPT Neptune Wellness Solutions	N/A	N/A	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A	N/A
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AFMD Affimed	0.13	1.93	1.93
GALT Galectin Therapeutics	N/A	0.08	0.08
NEPT Neptune Wellness Solutions	N/A	0.23	0.10
OASM Oasmia Pharmaceutical AB (publ)	N/A	0.80	0.73
THTX Theratechnologies	N/A	0.84	0.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AFMD Affimed	30.82%
GALT Galectin Therapeutics	11.68%
NEPT Neptune Wellness Solutions	14.44%
OASM Oasmia Pharmaceutical AB (publ)	0.11%
THTX Theratechnologies	N/A

Insider Ownership

Company	Insider Ownership
AFMD Affimed	3.80%
GALT Galectin Therapeutics	50.10%
NEPT Neptune Wellness Solutions	5.10%
OASM Oasmia Pharmaceutical AB (publ)	N/A
THTX Theratechnologies	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AFMD Affimed	200	16.10 million	15.49 million	Optionable
GALT Galectin Therapeutics	9	63.29 million	31.58 million	Optionable
NEPT Neptune Wellness Solutions	58	4.53 million	4.30 million	Not Optionable
OASM Oasmia Pharmaceutical AB (publ)	57	74.97 million	N/A	Not Optionable
THTX Theratechnologies	140	45.98 million	N/A	Optionable

GALT, AFMD, NEPT, THTX, and OASM Headlines

Recent News About These Companies

Theratechnologies (NASDAQ:THTX) Announces Quarterly Earnings Results

July 9, 2025 | marketbeat.com

Theratechnologies Reports Financial Results for the Second Quarter 2025

July 9, 2025 | globenewswire.com

Theratechnologies: Beyond GLP-1s - Is Tesamorelin's Exit A Sign Of New Metabolic Opportunities?

July 7, 2025 | seekingalpha.com

Future Pak to buy Theratechnologies for $254 million

July 4, 2025 | thepharmaletter.comT

Theratechnologies Stock (NASDAQ:THTX), Insider Trading Activity

July 3, 2025 | benzinga.com

Theratechnologies Inc. (THTX) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

Theratechnologies Stock Short Interest Report | NASDAQ:THTX - Benzinga

July 3, 2025 | benzinga.com

Theratechnologies shareholders should take the deal, Research Capital says

July 3, 2025 | cantechletter.comC

Theratechnologies to be bought by CB Biotechnology for $254M

July 3, 2025 | msn.com

Theratechnologies to Announce Second Quarter 2025 Financial Results

July 3, 2025 | globenewswire.com

Theratechnologies' (THTX) Hold Rating Reaffirmed at Jones Trading

July 3, 2025 | marketbeat.com

Theratechnologies to be Acquired by Future Pak Affiliate

July 2, 2025 | tipranks.com

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

July 2, 2025 | finance.yahoo.com

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

July 2, 2025 | globenewswire.com

Theratechnologies Reports on its Annual Meeting of Shareholders

May 29, 2025 | globenewswire.com

Theratechnologies announces annual shareholder meeting

May 4, 2025 | uk.investing.com

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

May 2, 2025 | globenewswire.com

Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer

April 18, 2025 | seekingalpha.com

Is Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?

April 18, 2025 | msn.com

Theratechnologies to further evaluate potential sale of the company

April 16, 2025 | markets.businessinsider.com

Theratechnologies Provides Update on Sale Process

April 15, 2025 | financialpost.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT, AFMD, NEPT, THTX, and OASM Company Descriptions

Affimed NASDAQ:AFMD

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Galectin Therapeutics NASDAQ:GALT

$2.80 -0.09 (-3.11%)

Closing price 04:00 PM Eastern

Extended Trading

$2.95 +0.15 (+5.36%)

As of 07:59 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Neptune Wellness Solutions NASDAQ:NEPT

Neptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada.

Oasmia Pharmaceutical AB (publ) NASDAQ:OASM

Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.

Theratechnologies NASDAQ:THTX

$3.14 -0.01 (-0.32%)

Closing price 04:00 PM Eastern

Extended Trading

$3.14 +0.00 (+0.16%)

As of 04:39 PM Eastern

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time